Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Infect. 2014 Jul;69(1):81-7. doi: 10.1016/j.jinf.2014.02.018. Epub 2014 Mar 14.

The E genotype of hepatitis B: clinical and virological characteristics, and response to interferon.

Author information

  • 1Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, Turin, Italy. Electronic address: lucio.boglione@gmail.com.
  • 2Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, Turin, Italy.
  • 3Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, C.so Svizzera 164, Turin, Italy. Electronic address: antonio.davolio@unito.it.

Abstract

OBJECTIVES:

10 hepatitis B virus (HBV) genotypes are known with different geographic distribution and response to interferon (IFN) therapy. The E genotype is the more prevalent genotype in West and Central Africa, but few data about response to IFN are available. We describe the epidemiological and clinical characteristics in a cohort of patients immigrants from Africa in our country with HBV E genotype chronic hepatitis infection (CHB).

METHODS:

63 patients with CHB and E genotype were included; 41 with CHB and low viral load were treated with PEG-IFN monotherapy; 10 with CHB and high viral load with sequential approach (entecavir and PEG-IFN). 12 patients with inactive CHB were followed with blood sample and abdomen ultrasonography every six months.

RESULTS:

The virological response in the monotherapy group was 17.9%. Hepatitis B surface antigen (HBsAg) loss was observed in 1 patient (2.5%); 56 patients (88%) showed at the time of diagnosis of CHB another infectious diseases that required specific treatment before PEG-IFN; this treatment was also affected by an higher incidence of side-effects (>50%). All patients with high viremia showed a primary non-response to PEG-IFN.

CONCLUSIONS:

The HBV E genotype evidences the worse response to PEG-IFN and maybe requires novel treatment options.

Copyright © 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

KEYWORDS:

E genotype; HBV; PEG-interferon; Serological response; Virological response

PMID:
24631900
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk